Sage Journals: Discover world-class research

Abstract

Because of the widespread prevalence of chronic obstructive pulmonary disease (COPD) and the important role of drug therapy in its management, there is significant opportunity for the pharmacist to interact with COPD patients. Whether educating patients or other health care providers about COPD, a knowledge of the treatment options and their correct application in these patients is essential for pharmacists today. This article reviews the pharmacological management of ambulatory COPD patients, including the roles of β-agonists, anticholinergics, theophylline, steroids, oxygen, and other treatment modalities. Copyright © 1992 by W.B. Saunders Company

Get full access to this article

View all access options for this article.

References

American Thoracic Society : Definitions and classifications of chronic bronchitis, asthma, and pulmonary emphysema. Am Rev Respir Dis 85:762-769, 1962

Gatz VP : Chronic obstructive airway disease, in Young LY , Koda-Kimble MA , Kradjan WA , et al (eds): Applied Therapeutics: The Clinical Use of Drugs. Vancouver, WA, Applied Therapeutics, 1988, pp 393-412

Lenfant C. : Lung research: Government and community. Am Rev Respir Dis 26:753-757,1982

Peto R. , Speizer FE , Cochrane AL , et al: The relevance in adults of airflow obstruction, but not of mucus hypersecretion, to mortality from chronic lung disease. Am Rev Respir Dis 128:491-500, 1983

Charan NE : Chronic obstructive pulmonary disease, in Vestal RE (ed): Drug Treatment in the Elderly. Boston, MA, ADIS Health Science Press, 1984, pp 89-107

Alexander MR , Taylor JW , Dull WL , et al: Therapy of chronic obstructive airways disease. Drug Intl Clin Pharm 18:279-291, 1984

Lam AL , Newhouse MT : Management of asthma and chronic airflow limitation: Are methylxanthines obsolete? Chest 98:44-52, 1990

Easton PA , Jadue C. , Dhingra S. , et al: A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 315:735-739, 1986

Gross NJ , Skordin MS : Role of the parasympathetic system in airway obstruction due to emphysema . N Engl J Med 311:421-425, 1984

10.

Skorodin MS : Pharmacologic management of obstructive lung disease: Current perspectives. Am J Med 81:8-15, 1986 (suppl 5A)

11.

Gross NJ : Ipratropium bromide. N Engl J Med 319:486-494, 1988

12.

Chapman KR : The role of anticholinergic bronchodilators in adult asthma and chronic obstructive pulmonary disease. Lung 168:295-303, 1990 (suppl)

13.

Teale C. , Pearson SB : Regular nebulised terbutaline in chronic obstructive airways disease: Dose-response studies fail to detect tolerance. Br J Clin Pharmacol 32:111-114, 1991

14.

Passmonte PM , Martinez AJ : Effect of inhaled atropine or metaproterenol in patients with chronic airway obstruction and therapeutic serum theophylline levels. Chest 85:610-615, 1984

15.

Braun SR , McKenzie WN , Copeland C. , et al: A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. Arch Intern Med 149:544-547, 1989

16.

Lipworth BJ , Tregaskis BF , McDevitt DG : Beta-adrenoceptor responses to inhaled salbutamol in the elderly. Br J Clin Pharmacol 28:725-729, 1989

17.

Kradjan WA , Driesner NK , Abuan TH , et al: Effect of age on bronchodilator response. Chest 101:, 1992 (in press)

18.

Georgopoulos D. , Wong D. , Anthonisen NR : Tolerance to beta2-agonists in patients with chronic obstructive-pulmonary disease. Chest 97:280-284, 1990

19.

Plummer AL : The development of drug tolerance to beta2 adrenergic agents. Chest 73:949-957, 1978

20.

Marini JJ , Lakshminarayan S. : The effect of atropine inhalation in "irreversible" chronic bronchitis . Chest 77:591-596,1980

21.

Spitzer WO , Suissa S. , Ernst P. , et al: The use of beta agonists and the risk of death and near death from asthma. N Engl J Med 326:501-506, 1992

22.

Gross NJ , Petty TL , Friedman M. , et al: Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: A three center study. Am Rev Respir Dis 139:1188-1191, 1989

23.

LeDoux EJ , Morris JF , Temple WP , et al: Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Chest 95:1013-1016,1989

24.

Lakshminarayan S. : Ipratropium bromide in chronic bronchitis/emphysema: A review of the literature. Am J Med 81:76-80, 1986 (suppl 5A)

25.

Kradjan WA , Smallridge RC , Davis R. , et al: Atropine serum concentrations after multiple inhaled doses of atropine sulfate. Clin Pharmacol Ther 38:12-15, 1985

26.

Groth ML , Langenback EG , Foster WM : Influence of inhaled atropine on lung mucociliary function in humans . Am Rev Respir Dis 144:1042-1047, 1991

27.

Guyatt GH , Townsend M. , Pugsley SO , et al: Bronchodilators in chronic air-flow limitation. Am Rev Respir Dis 135:1069-1074, 1987

28.

Landsberg KF , Vaughan LM , Heffner JE : The effect of theophylline on respiratory muscle contractility and fatigue. Pharmacotherapy 10:271-279, 1990

29.

Nicotra MB , Rivera M. , Awe RJ : Antibiotic therapy for acute exacerbations of chronic bronchitis. Ann Intern Med 97:18-21, 1982

30.

Anthonisen NR , Manfreda J. , Warren Cpw , et al: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196-204,1987

31.

Hudson LD , Monti CM : Rationale and use of corticosteroids in chronic obstructive pulmonary disease . Med Clin North Am 74:661-690, 1990

32.

Strain DS , Kinasemitz GT , Franco DP , et al: Effect of steroid therapy on exercise performance in patients with irreversible chronic pulmonary disease. Chest 88:718, 1985

33.

Shim CS , Williams MH Jr : Aerosol beclomethasone in patients with steroid responsive chronic obstructive pulmonary disease. Am J Med 78:655-658, 1985

34.

Harding SM , Freedman S. : A comparison of oral and inhaled steroids in patients with chronic airways obstruction: Features determining response. Thorax 33:214-218, 1978

35.

O'Donnell JT: Adverse effects of corticosteroids. Pharmacy Practice 11:256-266, 1989

36.

Dorow P. : Mucolytics: When dispensable, when necessary ? Lung 168:622-626,1990 (suppl)

37.

Sheffner AL : The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-1-cysteine. Ann N Y Acad Sci 106:298-310, 1963

38.

Aylward M. , Maddock J. , Dewland P. : Clinical evaluation of acetylcysteine in the treatment of patients with chromic obstructive bronchitis: A balanced double-blind trial with placebo control . Eur J Respir Dis 61:81-89, 1980 (suppl 111)

39.

Bowman G. , Backer U. , Carsson S. , et al: Oral acetylcysteine reduces exacerbations rate in chronic bronchitis: A report of a trial organized by the Swedish Society for Pulmonary Diseases . Eur J Respir Dis 64:405-415,1983

40.

Chodosh S. : Acetylcysteine in chronic bronchitis. Eur J Respir Dis 61:90-92, 1980 (suppl 111)

41.

Chodosh S. : Objective sputum changes associated with glyceryl guaiacolate in chronic bronchial diseases. Bull Physiol Path Resp 9:452-457, 1973

42.

Hirsch SR , Viernes PF , Kory RC : The expectorant effect of glyceryl guaiacolate in patients with chronic bronchitis . Chest 63:9-14, 1973

43.

Petty TL : The national mucolytic study. Chest 97:75-83, 1990

44.

Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 93:391-398,1980

45.

Medical Research Council Working Party: Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 28:681-686,1981

46.

Levi-Valensi P. , Weitzenblum E. , Pedineielli JL , et al: Three month follow-up of arterial blood gas determinations in candidates for long-term oxygen therapy. Am Rev Respir Dis 133:547-551, 1986

47.

Vergeret J. , Brambilla C. , Mourier L. : Portable oxygen therapy: Use and benefit in hypoxemic COPD patients on long-term oxygen therapy. Eur Respir J 2:20-35, 1989

48.

Evans TW , Waterhous JC , Carter A. , et al: Short burst oxygen therapy for breathlessness in chronic obstructive airways disease. Thorax 41:611-615, 1986

49.

Liss HP , Grant Bjb : The effect of nasal flow on breathlessness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 137:1285-1288, 1988

50.

Pingleton SK : Home oxygen therapy for ambulant COPD patients . J Respir Dis 3:35-45, 1982

51.

Timms RM , Dawson A. : An analysis of the practice of out-patient oxygen therapy. Chest 80:354-355, 1981 (abstr)

52.

Pierce JA : Antitrypsin and emphysema. JAMA 259: 2890-2895, 1988

53.

Hubbard RL , Crystal RG : Augmentation therapy of AAT deficiency. Eur Respir J 3:44s-52s, 1990 (suppl 9)

54.

Wewers MD , Cusolaro MA , Sellers SE , et al: Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema. N Engl J Med 316:1055-1062, 1987

55.

Moser KM , Smith RM , Spragg RG , et al: Intravenous administration of alpha-1-proteinase inhibitor in patients of PiZ and PiM phenotype. Am J Med 84:70-73, 1988 (suppl 6A)

56.

Ulmer WT , Schmidt EW , Rasche B. : Long-term effect on lung function of alpha-1-protease inhibitor substitution therapy in COPD patients with PiZZ phenotype. Eur Respir J 3:21s-22s, 1990 (suppl 9)

57.

Hubbard RL , Sellers S. , Czeski D. , et al: Biochemical efficacy and safety of monthly augmentation therapy for alpha-1-antitrypsin deficiency. JAMA 260:1259-1264, 1988

58.

Hubbard RL , Brantly NL , Sellers S. , et al: Antineutrophil elastase defenses of lower respiratory tract in alpha-1-antitrypsin deficiency directly augmented with an aerosol of alpha-1-antitrypsin . Ann Intern Med 3:206-212, 1989

The Pharmacological Treatment of Ambulatory Chronic Obstructive Pulmonary Disease Patients

Abstract

Get full access to this article

References